Peter Attia· MD
anecdotally people said that I never saw a trial it looked at that
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
anecdotally people said that I never saw a trial it looked at that
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
where did all this hydrophilic lipophilic stuff come from the first two competitive statins on the market were Simba Statin which was MC's most potent Statin more potent and their Lovastatin or meore so everybody jumped on zil Cor or simvastatin but Bristol Meer squid made pravastatin hydrophilic and there was a lot of thought looking at other biomarkers that the and even catabolism that the hydrophilic statins were safer than the others